Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yiqi Yangyin Huoxue Lishui combined with aflibercept for diabetic macular edema
ChiCTR2100046527Phase 4Recruiting
- Sponsor
- Aier Eye Hospital
- Start
- Jun 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of aflibercept in diabetic macular edema (DME) (2 arms), sponsored by Aier Eye Hospital. Primary endpoints: Best corrected visual acuity and Mean retinal thickness and blood flow in the central 1 mm foveal macular area. Started Jun 2021; status: recruiting.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ChiCTR2100046527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046527.